Age-Related Eye Health: Proactive vs. Reactive Care

age-related-eye-health-proactive-vs-reactive-care.jpgWith an aging population, it’s important for eye care professionals to know the changes that occur throughout the years. Declining vision is a typical side effect of aging, with patients noticing changes between the ages of 40 and 60 years old. While declining vision may be unavoidable, Dr. Raymond Brill knows that age-related eye health concerns don’t have to be part of the picture.

Age-Related Eye Health Concerns

Age-related eye health concerns affect nearly 1.8 million people, while another 7.3 million are at risk. Affecting mostly adults over 50, it damages the macula and destroys central vision. Symptoms include:
  • Loss of visual sharpness
  • Straight lines appear wavy
  • Objects appear distorted
  • Dark spot takes over central vision
Once central vision is gone, there is no recovering it. While total vision loss will not occur, simple daily tasks become difficult. age-related-eye-health-proactive-vs-reactive-care-1.jpg

Risks for Developing Age-Related Eye Health Concerns

The main risk factor for this eye health concern is in the name: age. Unfortunately, aging is unavoidable, like several other risk factors for age-related eye health concerns:
  • Family history
  • Light skin & eyes
  • Female
However, there are also some modifiable risk factors that you can advise patients to start mitigating:
  • Smoking
    • “Stop smoking, or better yet, don’t start.”
  • Unprotected sun exposure
    • “Wear sunglasses or a brimmed hat outside during the day.”
  • High blood pressure & cholesterol levels
    • “Be diligent in monitoring your levels and keeping them in check.”
  • Obesity
  • Cardiovascular diseases
  • Unhealthy lifestyle
    • “I’m going to tell you the same things you’ve been hearing and a new one:
      • Exercise regularly throughout the week (walk, run, ride a bike, etc.).
      • Eat a better diet that includes leafy greens, fruits, vegetables, and fish.
      • Take an eye health nutraceutical to get adequate amounts of zeaxanthin, lutein, and other eye-healthy nutrients.”

Proactive vs. Reactive

While patients can’t change their past risks like sun exposure and smoking, they can begin proactively making changes to help reduce their chances of developing age-related eye health concerns. It’s important that patients understand that once they start to notice symptoms, their eyes have already been damaged. Proactive care is the best way to help patients have positive outcomes, and it’s far less expensive for them in the long run. A comprehensive eye exam is the best way to identify age-related eye health concerns, but there are other methods of early risk detection. Dr. Brill utilizes macular pigment optical density (MPOD) measurement as another way to identify a modifiable risk factor for his patients.
“By using this technology, we’re able to identify decreases in macular function, assess the risk factors of developing years before , and provide action steps to help mitigate the risk of developing . “
An action step that’s common for those with age-related eye health concerns is nutritional intervention. Nutrition can better eye health and keep age-related eye health concerns from getting worse. Dr. Brill trusts EyePromise®eye health nutraceuticals for his patients and the QuantifEye® MPS II MPOD measurement instrument in his practice. age-related-eye-health-proactive-vs-reactive-care-2.jpg Though getting older is something that cannot be controlled, patients’ risk of developing age-related eye health concerns can be. Lifestyle changes and proactive care are two ways patients can start to mitigate their risk. Offering your patients the best proactive care starts by knowing and evaluating their risks, and then knowing what next steps to take.

https://www.lvcenter4sight.com/age-related-eye-health-proactive-vs-reactive-care/

Comments

Post a Comment

Popular posts from this blog

FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10

Editas Medicine , a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth. Known as EDIT-101, the treatment will be evaluated in a Phase 1/2, dose-escalation clinical trial.  The company expects to enroll 10 to 20 patients. Further details and contact information for the study will be listed soon at www.clinicaltrials.gov . EDIT-101 targets a specific mutation, “c.2991+1655A>G” in intron 26, of the CEP290 gene. Editas has earned a $25 million milestone payment from Allergan as part of a drug-development alliance. “We are very pleased with this historic milestone in the treatment of inherited retinal diseases,” says Stephen Rose, PhD, chief scientific officer, Foundation Fighting Blindness. “EDIT-101 is the fi...
Read more

Cataract Surgery Leads to Longer Life in Women

Image
Written by Dr. David Evans Last modified on September 6, 2018 An article I wrote back in April described a National Bureau of Economic Research study that concluded cataract surgery patients have a life expectancy 1.8 years longer than people with cataracts who do not undergo surgery. Much of that piece focused on the finding that people, who have vision diminished by cataracts, are less likely to be active, and more likely to suffer accidental falls and related injuries. As a follow-on, a new study published in JAMA Ophthalmology suggests an even stronger link between cataract surgery and mortality risk. About the Study The genesis of this study was something completely different than evaluating effects of cataract vision loss. Its original purpose was to evaluate the effects of hormone therapy and dietary changes in postmenopausal women. That study was cut short once it was determined that hormone therapy increased the risk of vascular events. Although the hormone therapy aspect ...
Read more

Vision Improvements Reported in ProQR’s Clinical Trial for LCA10 Treatment

Image
ProQR, a biotech company in the Netherlands, ha s reported vision improvements for patients in a  Phase 1/2 clinical trial for QR-110 , a therapy for people with  Leber congenital amaurosis  10 (LCA10), which is caused by the p.Cys998X mutation in the CEP290 gene. The mutation is estimated to affect about 2,000 people in the Western world. The company reported that 60 percent of su bjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course . The treatment was also safe for patients. As a result of the encouraging interim results, ProQR has concluded the Phase 1/2 trial and plans to move the treatment into a Phase 2/3 clinical trial. Ten people were treated in the Phase 1/2 study. Results from the interim analy sis were presented on September 5, 2018, at the Retinal Degeneration 2018 meeting in Killarney,   Ireland , by principal investigator   Artur Cideciyan , PhD , research professor of ophthalmology at the   Scheie Eye Ins...
Read more